About
Introduction
Professional Background
Sonja Buschow studied Medical Biology at Utrecht University and at this location later also obtained her PhD on the mechanisms of formation, secretion and targeting of Dendritic cell (DC) and B cell exosomes. In 2006 she moved to the UMC St Radboud/ RIMLS in Nijmegen where she applied mass spectrometry and transcriptome analysis to study the molecular dynamics of phagosomes, DCs and blood cells to facilitate the use of dendritic cells for cancer immunotherapy. In 2014 she started at the Erasmus MC department of Gastroenterology & hepatology to develop antigen-based immunotherapy for hepatitis B infection and related liver cancer. At this department she now leads her own research group.
Research Interests
Sonja Buschow’s main research interest is (the regulation of) antigen presentation in professional antigen presenting cells as well as diseased target cells. Knowledge obtained she aims to apply to the development of immunotherapy in general, and more specifically for the development of a therapeutic vaccine for chronic hepatitis B (HBV) and HBV related hepatocellular carcinoma (HCC) and also for other gastrointestinal diseases including Pancreatic ductal adeno carcinoma (PDAC).
Sonja Buschow studied Medical Biology at Utrecht University and at this location later also obtained her PhD on the mechanisms of formation, secretion and targeting of Dendritic cell (DC) and B cell exosomes. In 2006 she moved to the UMC St Radboud/ RIMLS in Nijmegen where she applied mass spectrometry and transcriptome analysis to study the molecular dynamics of phagosomes, DCs and blood cells to facilitate the use of dendritic cells for cancer immunotherapy. In 2014 she started at the Erasmus MC department of Gastroenterology & hepatology to develop antigen-based immunotherapy for hepatitis B infection and related liver cancer. At this department she now leads her own research group.
Research Interests
Sonja Buschow’s main research interest is (the regulation of) antigen presentation in professional antigen presenting cells as well as diseased target cells. Knowledge obtained she aims to apply to the development of immunotherapy in general, and more specifically for the development of a therapeutic vaccine for chronic hepatitis B (HBV) and HBV related hepatocellular carcinoma (HCC) and also for other gastrointestinal diseases including Pancreatic ductal adeno carcinoma (PDAC).
Field(s) of expertise
Dendritic cell (DC) biology, Antigen processing and presentation, HLA-peptidomics, cross presentation, Tumor Immunology, Antigen-based Immunotherapy, Therapeutic vaccination, Hepatitis B virus (HBV) infection, Hepatocellular Carcinoma (HCC), Pancreatic ductal adeno carcinoma (PDAC)
Education and career
1997-2002 Master Biomedical sciences Utrecht University.
2002-2006 PhD at the department of Biochemistry and Cell biology, faculty of veterinary sciences, Utrecht University on ""mechanisms of formation, secretion and targeting of Dendritic cell (DC) and B cell exosomes
2002-2006 PhD at the department of Biochemistry and Cell biology, faculty of veterinary sciences, Utrecht University on ""mechanisms of formation, secretion and targeting of Dendritic cell (DC) and B cell exosomes
Publications
Teaching activities
- Member of the core teacher team of the EMC research master ""infection and Immunity
- Thesis supervision:
Dr. Till Mathan “Resolving DC subset characteristics by using -omics to improve DC immunotherapies”, April 2018, Radboud UMC Nijmegen - Supervision of 4 current PhD students
Other positions
Principle coordinator Academic Centre of Excellence (ACE) “Tumor Immunology and Immunotherapy"
Scholarships, grants, and awards
- 2018 Erasmus MC pilot grant (co-applicant)
- 2017 Erasmus MC PhD grant
- 2017 MLDS TKI grant
- 2016 KWF Unique High risk
- 2015 NVGE Gastrostart
